



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Kynurenic acid-d₅

Cat. No.:	HY-100806S
CAS No.:	350820-13-2
Molecular Formula:	C ₁₀ H ₂ D ₅ NO ₃
Molecular Weight:	194.2
Target:	Apoptosis; iGluR; Endogenous Metabolite; CXCR; GPR35; Isotope-Labeled Compounds
Pathway:	Apoptosis; Membrane Transporter/Ion Channel; Neuronal Signaling; Metabolic Enzyme/Protease; GPCR/G Protein; Immunology/Inflammation; Others
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

0.1 M NaOH : 12.5 mg/mL (64.37 mM; ultrasonic and adjust pH to 9 with NaOH)
 0.1 M NaOH : 12.5 mg/mL (64.37 mM; ultrasonic and adjust pH to 9 with NaOH)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		5.1493 mL	25.7467 mL	51.4933 mL
	5 mM		1.0299 mL	5.1493 mL	10.2987 mL
	10 mM		0.5149 mL	2.5747 mL	5.1493 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	Kynurenic acid-d ₅ is the deuterium labeled Kynurenic acid. Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8[1][2].
IC ₅₀ & Target	NMDA Receptor
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Wang J, et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. *J Biol Chem*. 2006 Aug 4;281(31):22021-8.
- [3]. Albuquerque EX, et al. Kynurenic acid as an antagonist of $\alpha 7$ nicotinic acetylcholine receptors in the brain: facts and challenges. *Biochem Pharmacol*. 2013 Apr 15;85(8):1027-32.
- [4]. Małaczewska J, et al. Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. *Cent Eur J Immunol*. 2014;39(1):6-13.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA